safety of glp 1 receptor agonists Efficacy and LY3298176, a novel dual GIP and GLP-1 agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial Understanding GLP-1 receptor agonists and

GLP-1RA-induced delays in Gastrointestinal motility: predicted effects on coadministered drug absorption by PBPK analysis

For all their promise, GLP-1 and dual GIP/GLP-1 receptor agonists have raised more questions, particularly regarding their long-term safety implications

With regard to the kidney, this is even less understood, but the issue may be clarified once major kidney studies of agonists such as the dual GIP/GLP-1 agonist tirzepatide are completed (discussed below)

Visual impairment and visual worsening No differences in visual impairment between groups were seen (Supplementary Table 3), with visual impairment being associated with visual impairment at baseline (M3: \(\beta\)=0.79, 95% CI 0.54, 1.03

Not all rodent studies report elevated BP in response to GLP-1R agonism, but dose could be a discriminatory factor

Higher efficacy Aside from pricing competition and label expansion, greater efficacy in HbA1c reduction and/or weight loss, reduced side-effects and increased patient convenience (eg an oral tablet rather than a subcutaneous injection) will also contribute to the success of new GLP-1s and associated weight loss medication